Democrats have survived vetting of the Medicare portions of their prescription drug reform plan but lost ground on a separate pillar that penalizes drug companies for raising prices on individuals with private health insurance, Senate Majority Leader Chuck Schumer said Saturday.
The announcement is a blow to the party's signature domestic policy bill, which is headed for a key vote later Saturday. However, Schumer underscored the upside: The Senate's nonpartisan rules referee, who decides which provisions are eligible for sidestepping a GOP filibuster under the chamber's strict rules, signed off on Medicare-related drug price negotiation.
"This is a major victory for the American people," Schumer said in a statement. "While there was one unfortunate ruling … the overall program remains intact and we are one step closer to finally taking on Big Pharma and lowering Rx drug prices for millions of Americans."
To change your alert settings, please go to https://www.politico.com/_login?base=https%3A%2F%2Fwww.politico.com/settings.
This email was sent to edwardlorilla1986.paxforex@blogger.com by: POLITICO, LLC 1000 Wilson Blvd. Arlington, VA, 22209, USA
Please click here and follow the steps to unsubscribe.
No comments:
Post a Comment